pre-IPO PHARMA

COMPANY OVERVIEW

MimiVax LLC, is a clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for cancer treatment. Its lead candidate, SurVaxM, an immunotherapy developed at Roswell Park Comprehensive Cancer Center, is currently undergoing Phase 1 study in multiple myeloma and Phase 2 study in glioblastoma.


LOCATION

  • Buffalo, NY, USA
  • Buffalo, NY, USA

  • THERAPEUTIC AREAS

  • Autoimmune Disease
  • Oncology
  • Oncology

  • WEBSITE

    https://mimivax.com


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    buffalo-capital-partners buffalo-capital-partners roswell-park-cancer-institute roswell-parkp-cancer-institute


    PRESS RELEASES


    Dec 15, 2022

    MimiVax Announces Positive Final Data from the Phase IIa Study of SurVaxM for Newly Diagnosed Glioblastoma Published Today in the Journal of Clinical Oncology


    Nov 15, 2021

    MimiVax, LLC Receives FDA Approval to Initiate a New Phase 2b Clinical Study for the Treatment of Newly Diagnosed Glioblastoma


    May 30, 2020

    MimiVax Phase 2 study of SurVaxM in combination with pembrolizumab opens for recurrent glioblastoma patients


    Nov 18, 2019

    MimiVax LLC and Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. announce exclusive licensing agreement on SurVaxM for glioblastoma treatment in China


    May 29, 2019

    MimiVax to present results of SurVaxM immunotherapy in glioblastoma at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting


    For More Press Releases


    Google Analytics Alternative